DiaMedica Therapeutics Inc. (DMAC)
$8.20-1.56%Close
BUYRECOVERY · day 48
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $442M
- Beta
- 0.91
- P/E (TTM)
- -11.29
- Short % float
- 20.62%
- Days to cover
- 23.3
- SI change
- +1.7%
- 1W
- -2.61%
- 1M
- +26.74%
- vs SPY 1W
- -3.03%
- vs SPY 1M
- +24.68%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
FAQ
- What is LOPJLB’s current signal on DMAC?
- LOPJLB’s latest quantitative signal on DiaMedica Therapeutics Inc. (DMAC) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is DMAC in?
- DiaMedica Therapeutics Inc. (DMAC) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does DiaMedica Therapeutics Inc. (DMAC) do?
- DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type …